143 related articles for article (PubMed ID: 25000456)
1. Palifermin reduces infection rate and hyperfibrinogenemia in patients treated with high-dose chemotherapy based on beam or BU-thiothepa.
Milone G; Leotta S; Cupri A; Fauci AL; Spina P; Parisi M; Berritta D; Tripepi G
Bone Marrow Transplant; 2014 Sep; 49(9):1193-7. PubMed ID: 25000456
[TBL] [Abstract][Full Text] [Related]
2. Keratinocyte growth factor is effective in the prevention of intestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study.
Tsirigotis P; Triantafyllou K; Girkas K; Giannopoulou V; Ioannidou E; Chondropoulos S; Kalli T; Papaxoinis G; Pappa V; Papageorgiou E; Economopoulos T; Ladas SD; Dervenoulas J
Bone Marrow Transplant; 2008 Sep; 42(5):337-43. PubMed ID: 18560408
[TBL] [Abstract][Full Text] [Related]
3. Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT.
Sellner L; Boumendil A; Finel H; Choquet S; de Rosa G; Falzetti F; Scime R; Kobbe G; Ferrara F; Delmer A; Sayer H; Amorim S; Bouabdallah R; Finke J; Salles G; Yakoub-Agha I; Faber E; Nicolas-Virelizier E; Facchini L; Vallisa D; Zuffa E; Sureda A; Dreger P;
Bone Marrow Transplant; 2016 Feb; 51(2):212-218. PubMed ID: 26569093
[TBL] [Abstract][Full Text] [Related]
4. High-dose CEB vs BEAM with autologous stem cell transplant in lymphoma.
Wang EH; Chen YA; Corringham S; Bashey A; Holman P; Ball ED; Carrier E
Bone Marrow Transplant; 2004 Oct; 34(7):581-7. PubMed ID: 15273714
[TBL] [Abstract][Full Text] [Related]
5. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial.
Clemmons AB; Orr J; Andrick B; Gandhi A; Sportes C; DeRemer D
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2065-2071. PubMed ID: 29906570
[TBL] [Abstract][Full Text] [Related]
6. Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation.
Nooka AK; Johnson HR; Kaufman JL; Flowers CR; Langston A; Steuer C; Graiser M; Ali Z; Shah NN; Rangaraju S; Nickleach D; Gao J; Lonial S; Waller EK
Biol Blood Marrow Transplant; 2014 Jun; 20(6):852-857. PubMed ID: 24607557
[TBL] [Abstract][Full Text] [Related]
7. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden.
Blijlevens N; de Château M; Krivan G; Rabitsch W; Szomor A; Pytlik R; Lissmats A; Johnsen HE; de Witte T; Einsele H; Ruutu T; Niederwieser D;
Bone Marrow Transplant; 2013 Jul; 48(7):966-71. PubMed ID: 23241739
[TBL] [Abstract][Full Text] [Related]
8. Morbidity and transplant-related mortality of CBV and BEAM preparative regimens for patients with lymphoid malignancies undergoing autologous stem-cell transplantation.
Puig N; de la Rubia J; Remigia MJ; Jarque I; Martín G; Cupelli L; Sanz GF; Lorenzo I; Sanz J; Martínez JA; Jiménez C; Sanz MA
Leuk Lymphoma; 2006 Aug; 47(8):1488-94. PubMed ID: 16966258
[TBL] [Abstract][Full Text] [Related]
9. Impact of palifermin on intestinal mucositis of HSCT recipients after BEAM.
Herbers AH; van der Velden WJ; de Haan AF; Donnelly JP; Blijlevens NM
Bone Marrow Transplant; 2014 Jan; 49(1):8-10. PubMed ID: 23955637
[TBL] [Abstract][Full Text] [Related]
10. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
Steingrimsdottir H; Gruber A; Björkholm M; Svensson A; Hansson M
Haematologica; 2000 Aug; 85(8):832-8. PubMed ID: 10942930
[TBL] [Abstract][Full Text] [Related]
11. The risk factors for oral mucositis and the effect of cryotherapy in patients after the BEAM and HD-l-PAM 200 mg/m(2) autologous hematopoietic stem cell transplantation.
Vokurka S; Bystricka E; Scudlova J; Mazur E; Visokaiova M; Vasilieva E; Brandejsova R; Chvojkova I; Vrabcova M; Vitkova J; Mjartanova D; Vodickova M; Bockova J; Streinerova K
Eur J Oncol Nurs; 2011 Dec; 15(5):508-12. PubMed ID: 21310656
[TBL] [Abstract][Full Text] [Related]
12. Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas.
Jo JC; Kim JS; Lee JH; Lee JH; Im SN; Lee SM; Yoon SS; Kim IH; Bae SH; Lee YJ; Choi Y; Lee WS
Ann Hematol; 2021 Jan; 100(1):189-196. PubMed ID: 33205337
[TBL] [Abstract][Full Text] [Related]
13. Thiotepa, Etoposide, Cyclophosphamide, Cytarabine, and Melphalan (TECAM) Conditioning Regimen for Autologous Stem Cell Transplantation in Lymphoma.
Grisariu S; Shapira MY; Or R; Avni B
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):272-279. PubMed ID: 29500148
[TBL] [Abstract][Full Text] [Related]
14. High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma.
Zaucha R; Gooley T; Holmberg L; Gopal AK; Press O; Maloney D; Bensinger WI
Leuk Lymphoma; 2008 Oct; 49(10):1899-906. PubMed ID: 18949614
[TBL] [Abstract][Full Text] [Related]
15. Gut protection by palifermin during autologous haematopoietic SCT.
Johansson JE; Hasséus B; Johansson P; Eklöf C; Ohman D; Stockelberg D
Bone Marrow Transplant; 2009 May; 43(10):807-11. PubMed ID: 19043460
[TBL] [Abstract][Full Text] [Related]
16. Use of an Oral Busulfan Test Dose in Patients Undergoing Hematopoietic Stem Cell Transplantation Treated With or Without Fludarabine.
de Castro FA; Simões BP; Godoy AL; Bertagnoli Trigo FM; Coelho EB; Lanchote VL
J Clin Pharmacol; 2016 Dec; 56(12):1555-1562. PubMed ID: 27130252
[TBL] [Abstract][Full Text] [Related]
17. Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgkin and non-Hodgkin lymphomas.
Sakellari I; Mallouri D; Batsis I; Apostolou C; Konstantinou V; Abela EM; Douka V; Marvaki A; Karypidis K; Iskas M; Baliakas P; Kaloyannidis P; Yannaki E; Sotiropoulos D; Kouvatseas G; Smias C; Anagnostopoulos A
Leuk Lymphoma; 2015; 56(11):3071-81. PubMed ID: 25760637
[TBL] [Abstract][Full Text] [Related]
18. Palifermin for oral mucositis in the high-dose chemotherapy and stem cell transplant setting: the Royal Adelaide Hospital Cancer Centre experience.
Keefe D; Lees J; Horvath N
Support Care Cancer; 2006 Jun; 14(6):580-2. PubMed ID: 16775651
[TBL] [Abstract][Full Text] [Related]
19. Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option.
Seropian S; Nadkarni R; Jillella AP; Salloum E; Burtness B; Hu GL; Zelterman D; Cooper DL
Bone Marrow Transplant; 1999 Mar; 23(6):599-605. PubMed ID: 10217191
[TBL] [Abstract][Full Text] [Related]
20. Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT).
Blazar BR; Weisdorf DJ; Defor T; Goldman A; Braun T; Silver S; Ferrara JL
Blood; 2006 Nov; 108(9):3216-22. PubMed ID: 16835378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]